Praxis Precision Medicines (PRAX) Price/OCF Ratio: History & Chart

Praxis Precision Medicines, Inc.(PRAX)

Biotechnology · Boston, MA

$277.42-6.14 (-2.17%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Boston, MA

168 employees

www.praxismedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marcio Silva De'Souza

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Praxis Precision Medicines, Inc. (PRAX)	$7.73B	N/A	N/A	N/A	N/A
HealthEquity, Inc. (HQY)vs ›	$7.66B	15.63	17.86	23.57	28.47
Cytokinetics, Incorporated (CYTK)vs ›	$7.64B	N/A	233.51	233.51	753.42
Hinge Health, Inc. (HNGE)vs ›	$7.61B	26.16	26.45	30.90	30.90
Caris Life Sciences, Inc. (CAI)vs ›	$7.92B	39.33	44.24	44.24	44.24
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.34B	N/A	92.16	72.78	54.91
Oscar Health, Inc. (OSCR)vs ›	$8.44B	1.93	3.82	5.82	6.60
Alkermes plc (ALKS)vs ›	$7.01B	27.91	18.37	14.40	23.38
Kymera Therapeutics, Inc. (KYMR)vs ›	$8.59B	N/A	31.83	31.73	31.73
Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›	$8.77B	N/A	89.68	89.68	63.13

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Praxis Precision Medicines, Inc. (PRAX)

$7.73B

N/A

HealthEquity, Inc. (HQY)vs ›

$7.66B

15.63

17.86

23.57

28.47

Cytokinetics, Incorporated (CYTK)vs ›

$7.64B

N/A

233.51

753.42

Hinge Health, Inc. (HNGE)vs ›

$7.61B

26.16

26.45

30.90

Caris Life Sciences, Inc. (CAI)vs ›

$7.92B

39.33

44.24

Ionis Pharmaceuticals, Inc. (IONS)vs ›

$7.34B

N/A

92.16

72.78

54.91

Oscar Health, Inc. (OSCR)vs ›

$8.44B

1.93

3.82

5.82

6.60

Alkermes plc (ALKS)vs ›

$7.01B

27.91

18.37

14.40

23.38

Kymera Therapeutics, Inc. (KYMR)vs ›

$8.59B

N/A

31.83

31.73

Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›

$8.77B

N/A

89.68

63.13

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

PRAX Price/OCF Ratio Metrics

PRAX Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics